Forecast
The analysts' average price target is €36.45 (+33.52%). The median is €35.54 (+30.18%).
| Buy |
Â
15 |
| Hold |
Â
2 |
| Sell |
Â
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Viridian reports strong launch of Lumvoa and outlines broader TED strategy
Viridian describes the launch of Lumvoa as successful: within six weeks it reached 95% of the top 2,000 prescribing physicians, and payers indicate reimbursement levels comparable to TEPEZZA. The company is relying on existing payer infrastructure but expects delayed revenue due to authorization processes and billing rules until delivery to specialty distributors. Viridian plans a subcutaneous version (Elegrobart) with a BLA filing in Q1 2027 and is also developing programs such as a TSHR antagonist and an FcRn therapeutic program to expand the franchise. Management sees substantial untapped market potential, especially among chronic TED patients, and emphasizes market expansion rather than zero-sum competition. » More on de.investing.com
Viridien reports strong order growth; stock jumps after Q2 data
Viridien’s stock rose about 14.7% after Q2 figures following a marked increase in the order backlog in geosciences to USD 306m (up 33% since March). Major project awards from IOCs and NOCs in the Gulf of Mexico, Africa and the Middle East drove the volume; analysts view this as an early sign of broader revenue recovery. The EDA segment reached an adjusted EBITDA margin of 60% and the company confirmed its full-year target of USD 100m net cash flow for 2026. Viridien also filed the interim report with the AMF, providing additional transparency and investor confidence. » More on de.investing.com
Viridian Therapeutics' Lumvoa seen as differentiated treatment for thyroid eye disease, analysts raise targets
Goldman Sachs raised its target for Viridian Therapeutics to $39 and kept a Buy rating, citing Lumvoa's stronger proptosis improvement, promising safety profile and more convenient dosing versus Tepezza. Truist raised its target to $38, reiterated Buy and highlighted Lumvoa's focus on underserved markets, parity pricing and projected significant 2027 revenue with a franchise extension planned for Q1 2027. Viridian's broader pipeline includes Veligrotrug, Elegrobart, an anti‑TSHR program and FcRn inhibitors VRDN‑008 and VRDN‑006. » More on finance.yahoo.com
Viridien expects markedly negative quarterly result and issues annual forecast
Viridien will release results for the quarter ended June 30, 2026 on July 30, 2026; one analyst estimates EPS for the most recent quarter at -1.81 USD per share versus 0.67 EUR a year earlier. Two analysts see quarterly revenue at 237.0 million USD versus 206.7 million EUR in the year-ago quarter. Five analysts forecast an average EPS of 9.94 USD for the current fiscal year and four analysts expect revenue averaging 1.12 billion USD (prior year 948.5 million EUR). » More on finanzen.net
Viridian Therapeutics gains commercial edge after Lumvoa approval as analysts raise price targets
Following FDA approval of Lumvoa, Viridian Therapeutics priced the treatment at $450,000 per course and secured a label covering both active and chronic thyroid eye disease, which analysts say strengthens its commercial position. Wedbush raised its price target to $43 and maintained an Outperform rating, citing limited payer resistance, while Truist increased its target to $38 and reiterated a Buy rating, noting Lumvoa's convenient dosing and expected rapid adoption. Viridian plans a subcutaneous formulation with a BLA submission expected in Q1 2027 and anticipates meaningful revenue by 2027 from the underpenetrated TED market. » More on finance.yahoo.com
Financials
In the last quarter, Viridian Therapeutics Aktie had revenue of €22.74m and net profit of -€89.35m
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 22.74m | 62.19% |
| Gross profit | 21.39m | 64.43% |
| Net profit | -89.35m | 203.07% |
| EBITDA | -89.28m | 208.81% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €3.1bn |
Number of shares | 113.56m |
52-week high/low | €31.25 - €12.01 |
| Dividends | No |
Beta | 0.96 |
P/E ratio | -7.74 |
PEG ratio | 0.42 |
P/B ratio | 5.85 |
P/S ratio | 129.32 |
Company profile
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
| Name | Viridian Therapeutics Aktie |
| CEO | Stephen F. Mahoney |
| Headquarters | Waltham,
ma USA |
| Website | |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| IPO | 18/06/2014 |
| Employees | 252 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | VRDN |
London Stock Exchange | 0K1R.L |
Frankfurt | 1S1.F |
DĂĽsseldorf | 1S1.DU |
London | 0K1R.L |